Table 6.
Descriptive MRI analysis of follow-up scan in active patients (severe versus nonsevere postfingolimod disease activity).
| Endpoint | Group | N | Median | IQR | NAs |
|---|---|---|---|---|---|
| T2 new lesion number at FU | Severe | 10 | 9 | [8–15] | 3 |
| T2 new lesion number at FU | Nonsevere | 14 | 2.5 | [1–4] | 10 |
| T2 new lesion volume at FU (mm3) | Severe | 10 | 2070.25 | [1027.075–2783.25] | 3 |
| T2 new lesion volume at FU (mm3) | Nonsevere | 14 | 193.45 | [79.025–448.825] | 10 |
| Median volume per T2 new lesion at FU (mm3) | Severe | 10 | 209.5 | [104.75–234] | 3 |
| Median volume per T2 new lesion at FU (mm3) | Nonsevere | 14 | 76.5 | [58.25–111.25] | 10 |
FGL, fingolimod; FU, follow-up; IQR, interquartile range; MRI, magnetic resonance imaging; NA, not available.
Follow-up cerebral MRIs available within 6 months after FGL cessation were analyzed quantitatively [median (IQR) time after FGL stop 101 days (52.25–136.25)].